AMENDMENT #2 TO THE INVESTIGATOR SPONSORED RESEARCH AGREEMENT AMGEN PROTOCOL NO. 20119244 BY AND BETWEEN THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY FOR STANFORD UNIVERSITY, ON BEHALF OF […***…], AND AMGEN INC.Investigator Sponsored Research Agreement • August 9th, 2021 • Amplitude Healthcare Acquisition Corp • Biological products, (no disgnostic substances) • California
This Amendment #2 (this “Amendment”) to the Agreement (as defined below) is entered into as of November 15, 2017 (the “Amendment Effective Date”) by and between Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (“Amgen”) and The Board of Trustees of the Leland Stanford Junior University for Stanford University, having a location at 3000 El Camino Real, Bldg 5, Suite 300, Palo Alto, CA 94306 (“Institution”), on behalf of […***…] (“Principal Investigator”). Capitalized terms used but not otherwise defined in this Amendment shall have the meanings assigned to such terms in the Agreement.
ContractInvestigator-Sponsored Research Agreement • April 25th, 2022
INVESTIGATOR-SPONSORED RESEARCH AGREEMENT This Investigator-Sponsored Research (“ISR”) Grant Agreement (“Agreement”) between Pfizer, spol. s r.o., with its registered address at Praha 5, Stroupežnického 17, PSČ 15000, ID No. 49244809, registered in the Commercial Register with the Municipal Court in Prague, Section C, Insert 20616 (“Pfizer”) and « Univerzita Karlova » with an address of Ovocný trh 560/5, Praha 1, Česká republika, PSČ 116 36, IČ: 00216208, concerning the part: 1. lékařská fakulta, Kateřinská 32, Praha 2, Česká republika,121 08, public university under the Act No. 111/1998 Sb., the Higher Education Act, as amanded, (“Institution”) is effective as of the date of the publishing the Agreement in the Contracts Registry pursuant to Act No. 340/2015 Coll. on the Registration of Contracts (“Effective Date”). MUDr. Pavla Pokorná, Ph.D., an employee or a contractor of Institution (“Coordinating Investigator”), has designed and intends to conduct a non-interventional study entitle
AMENDMENT #1 TO THE INVESTIGATOR SPONSORED RESEARCH AGREEMENT AMGEN PROTOCOL NO. 20119244 BY AND BETWEEN THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY FOR STANFORD UNIVERSITY, ON BEHALF OF […***…], AND AMGEN INC.Investigator Sponsored Research Agreement • August 9th, 2021 • Amplitude Healthcare Acquisition Corp • Biological products, (no disgnostic substances) • California
This Amendment #1 (this “Amendment”) to the Agreement (as defined below) is entered into as of February 27, 2017 (the “Amendment Effective Date”) by and between Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (“Amgen”) and The Board of Trustees of the Leland Stanford Junior University for Stanford University, having a location at 3000 El Camino Real, Bldg 5, Suite 300, Palo Alto, CA 94306 (“Institution”), on behalf of […***…] (“Principal Investigator”). Capitalized terms used but not otherwise defined in this Amendment shall have the meanings assigned to such terms in the Agreement.
INVESTIGATOR SPONSORED RESEARCH AGREEMENT Amgen Protocol No. 20119244Investigator Sponsored Research Agreement • August 9th, 2021 • Amplitude Healthcare Acquisition Corp • Biological products, (no disgnostic substances) • California
This Investigator Sponsored Research Agreement (“Agreement”), effective as of June 18, 2013 (the “Effective Date”), is entered into by and between The Board of Trustees of the Leland Stanford Junior University for Stanford University, having a location at 1705 El Camino Real, Palo Alto, CA 94306 (“Institution”), on behalf of […***…] (“Principal Investigator”) and Amgen Inc., a Delaware corporation with its principal office and place of business at One Amgen Center Drive, Thousand Oaks, California 91320 (hereinafter “Amgen”).
